创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: iHuPBMC-B Platform Introduction

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-01 10:39
  • Views:

(Summary description)InnoModels Biotechnology has always been committed to advancing life science research, and its latest research achievement, the iHuPBMC-B platform, is leading a new direction in single-cell sequencing technology. iHuPBMC-B platform, with its unique advantages, provides researchers with a powerful tool to help them in complex biological samples to accurately resolve gene expression in individual cells

InnoModels: iHuPBMC-B Platform Introduction

(Summary description)InnoModels Biotechnology has always been committed to advancing life science research, and its latest research achievement, the iHuPBMC-B platform, is leading a new direction in single-cell sequencing technology. iHuPBMC-B platform, with its unique advantages, provides researchers with a powerful tool to help them in complex biological samples to accurately resolve gene expression in individual cells

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-01 10:39
  • Views:
Information

InnoModels Biotechnology has always been committed to advancing life science research, and its latest research achievement, the iHuPBMC-B platform, is leading a new direction in single-cell sequencing technology. iHuPBMC-B platform, with its unique advantages, provides researchers with a powerful tool to help them in complex biological samples to accurately resolve gene expression in individual cells.
First, the iHuPBMC-B platform is extremely sensitive. It can detect gene expression changes as low as 0.01%, enabling researchers to more accurately capture minute differences at the single-cell level. This is critical for understanding cellular processes in development, differentiation, and disease occurrence.
Second, the iHuPBMC-B platform has excellent specificity. Through the use of advanced primer design and optimized experimental protocols, the platform is able to accurately identify and differentiate gene expression, reducing the possibility of false positives and false negatives and ensuring the reliability of research results.

 


In addition, the iHuPBMC-B platform is easy to operate, greatly reducing the complexity of experiments. Researchers can easily access and analyze data without having a deep background in bioinformatics. Meanwhile, the platform provides a series of analysis tools and visualization software to help users dig deeper into the data and obtain more valuable discoveries.
Finally, the iHuPBMC-B platform has good reproducibility and scalability. By using the same platform for multiple experiments, researchers can ensure the consistency of results. In addition, the platform supports multiple types of samples, enabling researchers to flexibly design experiments according to research needs.
In summary, the iHuPBMC-B platform from InnoModels Biotechnology provides strong support for research in the field of single-cell sequencing with its sensitivity, specificity, simplicity, reproducibility and scalability. In the future, with the continuous advancement of technology and the expansion of application areas, we have reason to believe that the iHuPBMC-B platform will play an even greater role in life science research. Whether for basic research, drug discovery or clinical diagnosis, iHuPBMC-B platform will provide scientists with more breakthrough discoveries and innovative possibilities.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司